Get started
Author

Chelsee J. Jensen

Observed names: Chelsee Jensen, Chelsee Jo Jensen, Jensen,Chelsee;Scheckel,Caleb;Go,Ronald;Desai,Aakash;Soefje,Scott;
Institution: Mayo Clinic
Observed institution: Mayo Clinic
ORCID: 0000-0003-1954-4414
Observed ORCID: 0000-0003-1954-4414
OpenAlex ID: A5045829196
Trends in Prices of Drugs Used to Treat Metastatic Non–Small Cell Lung Cancer in the US From 2015 to 2020
2022 · Aakash Desai, Caleb Scheckel, et al. · JAMA Network Open · 43
PDF
Economic Cost and Sustainability of Oral Therapies in Precision Oncology
2022 · Aakash P. Desai, Caleb J. Scheckel, et al. · JCO Oncology Practice · 8
Non-neutralizing antibodies and limitations of serologic testing for severe acute respiratory syndrome coronavirus 2 in patients receiving immunoglobulin replacement products
2020 · Deepti Vellaichamy Manian, Chelsee Jensen, et al. · Annals of Allergy Asthma & Immunology · 7
PDF
Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization
2025 · Jenna R. Puttkammer, Jason N. Barreto, et al. · JCO Oncology Practice · 6
Implementing and Optimizing Biosimilar Use at Mayo Clinic
2022 · Chelsee J. Jensen, Eric M. Tichy, et al. · Mayo Clinic Proceedings · 5
Multiple Myeloma: Current Clinical Landscape and Compounding Costs
2023 · Kelsey Beck, Tyler Sandahl, et al. · Current Hematologic Malignancy Reports · 3
The high cost burden of third- to fifth-line treatments for multiple myeloma: unsustainable and unaffordable
2021 · Chelsee Jensen · Journal of Managed Care & Specialty Pharmacy · 3
PDF
Subcutaneous Immunotherapies in Solid Tumors: Are We Truly Expanding Access and Efficiency?
2025 · Gogo-ogute Ibodeng, Chelsee Jensen, et al. · JCO Oncology Practice · 2
Analysis of Medicare Expenditure for Discarded Infused Cancer Therapeutics From 2017-2020
2023 · Aakash Desai, Alexander Xiao, et al. · Mayo Clinic Proceedings · 2
Neulasta Onpro: A Coup de Grâce?
2023 · Jensen,Chelsee;Scheckel,Caleb;Go,Ronald;Desai,Aakash;Soefje,Scott; · The American Journal of Managed Care · 2
The economic cost and sustainability of the precision oncology promise.
2021 · Aakash Desai, Chelsee Jensen, et al. · Journal of Clinical Oncology · 1
Dose Optimization of Immune Checkpoint Inhibitors: A Policy opportunity to reduce costs and improve access to immunotherapy in the United States
2026 · Sameer Deshmukh, Arthi Sridhar, et al. · Journal of Cancer Policy
Pricing for Oncology Biosimilars
2026 · Chelsee Jensen, Eric Tichy · JAMA
30 years of classical hematology drugs in the US: Approvals, costs, and sales
2025 · Lewis Go, Lucas Go, et al. · Blood
PDF
The three-fer: How biosimilars reduce cost, expand access, and improve margin
2025 · Tina M. Seekamp, Michael Hamacher, et al. · Journal of the American Pharmacists Association
Erratum: Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization
2025 · Jenna R. Puttkammer, Jason N. Barreto, et al. · JCO Oncology Practice
Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization
2024 · Tyler B. Sandahl, Jenna Puttkammer, et al. · Blood
Contemporary Intravenous Iron Usage and Safety Patterns
2023 · Richard C. Godby, Sarah A. Chase, et al. · Blood
PDF
Tailored doses, tailored savings: Optimizing dosing strategies of immune checkpoint inhibitors.
2023 · Aakash Desai, Chelsee Jensen, et al. · JCO Oncology Practice
PDF
Clicks away from reduced healthcare expenditures: leveraging the electronic health record to reinforce education efforts
2022 · Chelsee Jo Jensen, Theresa Honsey, et al. · BMJ Health & Care Informatics
PDF
Medicare expenditures for discarded oncology therapies.
2022 · Caleb Scheckel, Aakash Desai, et al. · Journal of Clinical Oncology
The Sustainability of Price Dynamics in Precision Hematology
2021 · Caleb J Scheckel, Aakash Desai, et al. · Blood
Works count: 23
Citation count: 84
H-index: 5
I10-index: 1
Year
Topic
Type